O2 RegenTech is a medical device startup that specializes in cost-effective, easy-to-use wound care solutions. Their primary product, OXAID™, is an oxygenating, moist, antimicrobial dressing to promote healing of chronic wounds such as diabetic foot ulcers.
Newchip is a six-month online accelerator that provides founders with tools and skills necessary to build, scale and fund their startups. According to O2 RegenTech’s co-founder, president and CEO, Andreas Inmann, the company hopes to further validate their product and market, connect with advisors and founders from a variety of industries around the world, and gain exposure for their startup. With more than 1,000 graduates, NewChip claims to be the top online accelerator with global access in the world.
“We’re very proud to have been chosen for the Newchip Accelerator,” he said. “It was not an easy process – a lot of work went into it with several interviews, a thorough vetting process, and we had to demonstrate traction in areas other than revenue. We’re at a point where we need to build awareness of the company and product, and this will help tremendously.”
O2 RegenTech came out of The University of Akron. They have received funding from the Great Lakes Innovation and Development Enterprise, NEO Innovation Fund, JumpStart Inc., Ohio Third Frontier, National Science Foundation and National Institutes of Health.